NRx Builds Momentum From FDA Progress To Strategic Expansion - NRX Pharmaceuticals (NASDAQ:NRXP)

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) , a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system (CNS) disorders, specifically suicidal bipolar depression, chronic pain and PTSD, is making further inroads on that front. The company just announced it completed an in-person meeting with the U.S. Food and Drug Administration (FDA) over NRX-100, its developmental drug for treating suicidal depression. NRX-100 is a preservative-fr ...